New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 21, 2014
08:18 EDTRGLSRegulus Therapeutics granted orphan drug designation for RG-012 by FDA
Regulus Therapeutics announced that the FDA has granted orphan drug designation to RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21, as a therapeutic for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy. In the near term, Regulus expects to initiate a natural history of disease study to gather further information about the progression of Alport syndrome and to inform future clinical development plans of RG-012, a key program under Regulus' 'Clinical Map Initiative'.
News For RGLS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
10:26 EDTRGLSHigh option volume stocks
Subscribe for More Information
October 29, 2014
15:44 EDTRGLSRegulus Therapeutics price target raised to $23 from $19 at Wedbush
Subscribe for More Information
06:46 EDTRGLSRegulus Therapeutics 5.294M share Secondary priced at $17.00
Subscribe for More Information
October 28, 2014
09:20 EDTRGLSOn The Fly: Pre-market Movers
Subscribe for More Information
October 27, 2014
18:26 EDTRGLSOn The Fly: After Hours Movers
Subscribe for More Information
16:01 EDTRGLSRegulus Therapeutics files to sell $80M of common stock
Subscribe for More Information
October 22, 2014
16:33 EDTRGLSOn The Fly: Closing Wrap
Subscribe for More Information
12:09 EDTRGLSOn The Fly: Midday Wrap
Subscribe for More Information
07:57 EDTRGLSRegulus Therapeutics to host conference call
Conference call to discuss interim results from the ongoing clinical study of RG-101 for treatment of HCV will be held on October 22 at 8:30 am. Webcast Link
07:34 EDTRGLSRegulus Therapeutics' RG-101 for hepatitis C shows positive results
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use